Review



lentivirus carrying short-hairpin rna (shrna), shtnnt1, shtnnt1 and a negative control (shctrl)  (Genechem)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Genechem lentivirus carrying short-hairpin rna (shrna), shtnnt1, shtnnt1 and a negative control (shctrl)
    Lentivirus Carrying Short Hairpin Rna (Shrna), Shtnnt1, Shtnnt1 And A Negative Control (Shctrl), supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/lentiviral+short+hairpin+rna++shrna++vector/pm40327295-156-7-16
    Average 90 stars, based on 1 article reviews
    lentivirus carrying short-hairpin rna (shrna), shtnnt1, shtnnt1 and a negative control (shctrl) - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: RPL6 Interacts with HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma.
    Article Snippet: All lentivirus-driven short hairpin RNAs (shRNAs) against target genes were purchased from GeneChem Co., Ltd. (Shanghai, China).

    Article Title: Identification of Versican as a target gene of the transcription Factor ZNF587B in ovarian cancer.
    Article Snippet: Ovarian cancer is the most lethal malignancy affecting the female reproductive system, with its progression and metastasis being significant contributors to patient mortality.. Our previous study identified the zinc finger protein ZNF587B as a potential tumor suppressor that inhibited the proliferation, migration and invasion of ovarian cancer cells, although the underlying mechanism remains elusive.. In this study, ZNF587B was demonstrated to bind directly to the promoter region of Versican (VCAN), a high molecular weight chondroitin sulfate glycoprotein, and repress its transcription using Chromatin immunoprecipitation-qPCR (ChIP-qPCR), luciferase reporter assays, and immunofluorescence (IF).

    Article Title: High extracellular matrix stiffness upregulates TNNT1 to awaken dormant tumor cells in liver metastatic niches of gastric cancer.
    Article Snippet: The lentivirus carrying short-hairpin RNA (shRNA), shTNNT1, shTnnt1 and a negative control (shCtrl) were constructed by Genechem Co., Ltd. (Shanghai) to facilitate stable knockdown of TNNT1 in human GC cells and Tnnt1 in murine GC cells.

    Article Title: Therapeutic potential of targeting PCLAF in endometrial cancer: Insights from Wnt/β-catenin and P53 regulatory mechanisms.
    Article Snippet: Lentiviral short hairpin RNA (shRNA) constructs specifically aimed at PCLAF were obtained from GeneChem Co., Ltd. (Shanghai, China).

    Article Title: High extracellular matrix stiffness upregulates TNNT1 to awaken dormant tumor cells in liver metastatic niches of gastric cancer
    Article Snippet: The lentivirus carrying short-hairpin RNA (shRNA), sh TNNT1 , shTnnt1 and a negative control (shCtrl) were constructed by Genechem Co., Ltd. (Shanghai) to facilitate stable knockdown of TNNT1 in human GC cells and Tnnt1 in murine GC cells.

    Article Title: RPL6 Interacts with HMGCS1 to Stabilize HIF-1α by Promoting Cholesterol Production in Hepatocellular Carcinoma.
    Article Snippet: To establish RPL6- or HMGCS1-knockdownHCC cells, lentivirus-driven short hairpin RNAs (shRNAs) were purchased from GeneChem Co., Ltd. (Shanghai, China).

    Infection:

    Article Title: Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Construct:

    Article Title: Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Expressing:

    Article Title: Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Article Title: BRD4 / MAP2K7 / PGF Signaling Axis Promotes Senescence and Extracellular Matrix Metabolism of Nucleus Pulposus Cells in Intervertebral Disk Degeneration
    Article Snippet: Brightfield images were acquired using an Olympus MA BX53 microscope, and quantification of the stained cells was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). .. Lentiviruses expressing short hairpin RNA (shRNA) targeting BRD4 (sh‐BRD4), MAP2K7 (sh‐MAP2K7), and PGF (sh‐PGF), along with scrambled control shRNA (sh‐NC) and lentiviruses overexpressing BRD4 (LV‐BRD4), MAP2K7 (LV‐MAP2K7), PGF (LV‐PGF), and a control lentivirus (LV‐NC) were purchased from GeneChem (Shanghai, China). ..

    Knockdown:

    Article Title: Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    Over Expression:

    Article Title: Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.
    Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

    shRNA:

    Article Title: BRD4 / MAP2K7 / PGF Signaling Axis Promotes Senescence and Extracellular Matrix Metabolism of Nucleus Pulposus Cells in Intervertebral Disk Degeneration
    Article Snippet: Brightfield images were acquired using an Olympus MA BX53 microscope, and quantification of the stained cells was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). .. Lentiviruses expressing short hairpin RNA (shRNA) targeting BRD4 (sh‐BRD4), MAP2K7 (sh‐MAP2K7), and PGF (sh‐PGF), along with scrambled control shRNA (sh‐NC) and lentiviruses overexpressing BRD4 (LV‐BRD4), MAP2K7 (LV‐MAP2K7), PGF (LV‐PGF), and a control lentivirus (LV‐NC) were purchased from GeneChem (Shanghai, China). ..

    Control:

    Article Title: BRD4 / MAP2K7 / PGF Signaling Axis Promotes Senescence and Extracellular Matrix Metabolism of Nucleus Pulposus Cells in Intervertebral Disk Degeneration
    Article Snippet: Brightfield images were acquired using an Olympus MA BX53 microscope, and quantification of the stained cells was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). .. Lentiviruses expressing short hairpin RNA (shRNA) targeting BRD4 (sh‐BRD4), MAP2K7 (sh‐MAP2K7), and PGF (sh‐PGF), along with scrambled control shRNA (sh‐NC) and lentiviruses overexpressing BRD4 (LV‐BRD4), MAP2K7 (LV‐MAP2K7), PGF (LV‐PGF), and a control lentivirus (LV‐NC) were purchased from GeneChem (Shanghai, China). ..



    Similar Products

    90
    Genechem lentivirus carrying short-hairpin rna (shrna), shtnnt1, shtnnt1 and a negative control (shctrl)
    Lentivirus Carrying Short Hairpin Rna (Shrna), Shtnnt1, Shtnnt1 And A Negative Control (Shctrl), supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/lentiviral+short+hairpin+rna++shrna++vector/pm40327295-156-7-16
    Average 90 stars, based on 1 article reviews
    lentivirus carrying short-hairpin rna (shrna), shtnnt1, shtnnt1 and a negative control (shctrl) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genechem lentiviral vectors interfering with ltk expression and the negative control shctrl
    Lentiviral Vectors Interfering With Ltk Expression And The Negative Control Shctrl, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/lentiviral+vectors+interfering+with+ltk+expression+and+the+negative+control+shctrl/pm40154092-94-9-14
    Average 90 stars, based on 1 article reviews
    lentiviral vectors interfering with ltk expression and the negative control shctrl - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genechem negative control shctrl
    Negative Control Shctrl, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/negative+control+sh+nc/pm40117061-48-11-24
    Average 90 stars, based on 1 article reviews
    negative control shctrl - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genechem negative control (shctrl)
    Negative Control (Shctrl), supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/negative+control++nc+/pm40016746-52-14-17
    Average 90 stars, based on 1 article reviews
    negative control (shctrl) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genechem and nonsilencing short hairpin rna (shctrl) as a negative control
    And Nonsilencing Short Hairpin Rna (Shctrl) As A Negative Control, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/and+nonsilencing+short+hairpin+rna++shctrl++as+a+negative+control/pm39477144-107-12-24
    Average 90 stars, based on 1 article reviews
    and nonsilencing short hairpin rna (shctrl) as a negative control - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Genechem shrna negative control (shctrl)
    Shrna Negative Control (Shctrl), supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/negative+control+shrna+sh+nc/pm39307375-79-12-6
    Average 90 stars, based on 1 article reviews
    shrna negative control (shctrl) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Shanghai Genechem Ltd negative control shrna shctrl
    Negative Control Shrna Shctrl, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/shrna+shctrl/pm37997821-50-14-21
    Average 90 stars, based on 1 article reviews
    negative control shrna shctrl - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Millipore negative‐control shrna (shctrl, mfcd07785395)
    <t>CircLARP1B</t> destabilizes LKB1 mRNA via perturbing HNRNPD. a–d) Stability assay of LKB1 mRNA and the steady levels of LKB1 protein (examined by western blotting) in human PLC cells (a,b) and murine Hepa1‐6 cells (c,d) treated siRNA against HNRNPD. siNC, negative control siRNA with scrambled sequences. e) Overall experimental strategy of eIF4E and eIF4G1 RIP assays. RNase I is introduced to digest unprotected RNAs across the IP procedure. Western blots showing HNRNPD knockdown efficiency and efficient IPs of eIF4E and eIF4G1 in PLC cells treated with siRNA against HNRNPD (right). ACTB protein acted as the loading control. f) Primers against various regions of LKB1 mRNA (top) and enrichment of LKB1 mRNA regions with eIF4E or eIF4G1 by RT‐qPCR (bottom). g,h) Stability assay of LKB1 mRNA (g) and the steady levels of LKB1 protein (h) in WT or circLARP1B‐Def PLC cells. i,j) Stability assay of Lkb1 mRNA (i) and the steady levels of Lkb1 protein (j) in Hepa1‐6 cells treated with shcircLARP1B or shCtrl. shCtrl, <t>shRNA</t> control that generates siRNA of scrambled sequences; shcircLARP1B, shRNA against the murine circLARP1B BSJ. k) In vitro competing assay of purified HNRNPD protein for equal moles of in vitro synthesized circLARP1B and LKB1 3′ UTR. An illustration of the assay was shown (top). Semiquantitative RT‐PCR gels and RT‐qPCR for circLARP1B and LKB1 3′ UTR were indicated (bottom). LKB1 3′ UTR, in vitro transcribed LKB1 3′ UTR fragments with the HNRNPD binding sequence. l) Association of LKB1 mRNA examined by RT‐qPCR of HNRNPD RIP in PLC cells treated with oligodeoxynucleotide antisense to two HNRNPD binding motifs in circLARP1B (ODN‐AS) or the control (ODN‐Ctrl, ODN with scrambled sequences). Two motifs with reverse complementary sequences were indicated with underlines. PS, phosphorothioate; 2′‐OMe, 2′‐ O ‐methyl. Western blot images indicate successful IP of HNRNPD protein. Enrichment, normalized to IgG. m) Western blotting and the corresponding quantification showing the steady level of LKB1 protein in PLC cells transfected with ODN‐AS or ODN‐Ctrl. (b,d,h,j,m) The grayscale statistics of western blotting were performed by ImageJ. (a–d,f–m) Data are shown as mean ± SD from three independent experiments. (a,c,g,i) P ‐values by two‐way ANOVA test. (b,d,f,h,j,l,m) P ‐values by two‐tailed unpaired Student's t ‐test.
    Negative‐Control Shrna (Shctrl, Mfcd07785395), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/negative+control+shrna++shctrl++mfcd07785395+/pmc10787103-334-19-30
    Average 90 stars, based on 1 article reviews
    negative‐control shrna (shctrl, mfcd07785395) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Vigene Biosciences its corresponding negative control (shctrl)
    <t>CircLARP1B</t> destabilizes LKB1 mRNA via perturbing HNRNPD. a–d) Stability assay of LKB1 mRNA and the steady levels of LKB1 protein (examined by western blotting) in human PLC cells (a,b) and murine Hepa1‐6 cells (c,d) treated siRNA against HNRNPD. siNC, negative control siRNA with scrambled sequences. e) Overall experimental strategy of eIF4E and eIF4G1 RIP assays. RNase I is introduced to digest unprotected RNAs across the IP procedure. Western blots showing HNRNPD knockdown efficiency and efficient IPs of eIF4E and eIF4G1 in PLC cells treated with siRNA against HNRNPD (right). ACTB protein acted as the loading control. f) Primers against various regions of LKB1 mRNA (top) and enrichment of LKB1 mRNA regions with eIF4E or eIF4G1 by RT‐qPCR (bottom). g,h) Stability assay of LKB1 mRNA (g) and the steady levels of LKB1 protein (h) in WT or circLARP1B‐Def PLC cells. i,j) Stability assay of Lkb1 mRNA (i) and the steady levels of Lkb1 protein (j) in Hepa1‐6 cells treated with shcircLARP1B or shCtrl. shCtrl, <t>shRNA</t> control that generates siRNA of scrambled sequences; shcircLARP1B, shRNA against the murine circLARP1B BSJ. k) In vitro competing assay of purified HNRNPD protein for equal moles of in vitro synthesized circLARP1B and LKB1 3′ UTR. An illustration of the assay was shown (top). Semiquantitative RT‐PCR gels and RT‐qPCR for circLARP1B and LKB1 3′ UTR were indicated (bottom). LKB1 3′ UTR, in vitro transcribed LKB1 3′ UTR fragments with the HNRNPD binding sequence. l) Association of LKB1 mRNA examined by RT‐qPCR of HNRNPD RIP in PLC cells treated with oligodeoxynucleotide antisense to two HNRNPD binding motifs in circLARP1B (ODN‐AS) or the control (ODN‐Ctrl, ODN with scrambled sequences). Two motifs with reverse complementary sequences were indicated with underlines. PS, phosphorothioate; 2′‐OMe, 2′‐ O ‐methyl. Western blot images indicate successful IP of HNRNPD protein. Enrichment, normalized to IgG. m) Western blotting and the corresponding quantification showing the steady level of LKB1 protein in PLC cells transfected with ODN‐AS or ODN‐Ctrl. (b,d,h,j,m) The grayscale statistics of western blotting were performed by ImageJ. (a–d,f–m) Data are shown as mean ± SD from three independent experiments. (a,c,g,i) P ‐values by two‐way ANOVA test. (b,d,f,h,j,l,m) P ‐values by two‐tailed unpaired Student's t ‐test.
    Its Corresponding Negative Control (Shctrl), supplied by Vigene Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/negative+control+shrna/pm37807064-187-20-25
    Average 90 stars, based on 1 article reviews
    its corresponding negative control (shctrl) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    96
    Addgene inc negative shrna control shctrl
    Fig. 3 A20 inhibited antitumor immune response in vivo. a The expression of A20 in mice CT26-luc-GFP cells. b The cell proliferation of CT26- luc-GFP cells detected by CCK8 kit, n = 4. c The experimental scheme of the animal study. d The in vivo images of mice tumors with different treatments were detected by the IVIS bioluminescence imaging system, n = 7. e Statistical analysis of total flux from the IVIS bioluminescence images. f The representative images of the metastatic nodes in lung from BALB/C mice. g The survival curve of mice, n = 7. h The experimental scheme of the animal study. i The images of tumors excised from BALB/C mice at the end of experiments, n = 6. j Tumor weights of the four treatment groups, n = 6. k Tumor growth curves of the four treatment groups, n = 6. l The images of tumors excised from BALB/C mice at the end of experiments, n = 8. m Tumor weights of the four treatment groups, n = 8. n Tumor growth curves of the four treatment groups, n = 8. o–v The infiltration of CD3 (+) (X400), CD8 (+) (X400), CD4 (+) (X200), and Granzyme B(+) (X400) T cells detected by immunohistochemical staining. p-value was calculated by one-way ANOVA analysis. <t>Shctrl+IgG,</t> n = 7, Shctrl+αPD-1, n = 5, A20sh4+IgG, n = 7, A20sh4+αPD-1, n = 3. w–y Flow cytometry analysis of CD8 (+) and CD4 ( + ) T cells of mice spleens (n = 4 per group). Data was represented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant
    Negative Shrna Control Shctrl, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/negative+control+shctrl/shRNA+(Plasmid+%2355783)/pm37607946-252-8-17
    Average 96 stars, based on 1 article reviews
    negative shrna control shctrl - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    Image Search Results


    CircLARP1B destabilizes LKB1 mRNA via perturbing HNRNPD. a–d) Stability assay of LKB1 mRNA and the steady levels of LKB1 protein (examined by western blotting) in human PLC cells (a,b) and murine Hepa1‐6 cells (c,d) treated siRNA against HNRNPD. siNC, negative control siRNA with scrambled sequences. e) Overall experimental strategy of eIF4E and eIF4G1 RIP assays. RNase I is introduced to digest unprotected RNAs across the IP procedure. Western blots showing HNRNPD knockdown efficiency and efficient IPs of eIF4E and eIF4G1 in PLC cells treated with siRNA against HNRNPD (right). ACTB protein acted as the loading control. f) Primers against various regions of LKB1 mRNA (top) and enrichment of LKB1 mRNA regions with eIF4E or eIF4G1 by RT‐qPCR (bottom). g,h) Stability assay of LKB1 mRNA (g) and the steady levels of LKB1 protein (h) in WT or circLARP1B‐Def PLC cells. i,j) Stability assay of Lkb1 mRNA (i) and the steady levels of Lkb1 protein (j) in Hepa1‐6 cells treated with shcircLARP1B or shCtrl. shCtrl, shRNA control that generates siRNA of scrambled sequences; shcircLARP1B, shRNA against the murine circLARP1B BSJ. k) In vitro competing assay of purified HNRNPD protein for equal moles of in vitro synthesized circLARP1B and LKB1 3′ UTR. An illustration of the assay was shown (top). Semiquantitative RT‐PCR gels and RT‐qPCR for circLARP1B and LKB1 3′ UTR were indicated (bottom). LKB1 3′ UTR, in vitro transcribed LKB1 3′ UTR fragments with the HNRNPD binding sequence. l) Association of LKB1 mRNA examined by RT‐qPCR of HNRNPD RIP in PLC cells treated with oligodeoxynucleotide antisense to two HNRNPD binding motifs in circLARP1B (ODN‐AS) or the control (ODN‐Ctrl, ODN with scrambled sequences). Two motifs with reverse complementary sequences were indicated with underlines. PS, phosphorothioate; 2′‐OMe, 2′‐ O ‐methyl. Western blot images indicate successful IP of HNRNPD protein. Enrichment, normalized to IgG. m) Western blotting and the corresponding quantification showing the steady level of LKB1 protein in PLC cells transfected with ODN‐AS or ODN‐Ctrl. (b,d,h,j,m) The grayscale statistics of western blotting were performed by ImageJ. (a–d,f–m) Data are shown as mean ± SD from three independent experiments. (a,c,g,i) P ‐values by two‐way ANOVA test. (b,d,f,h,j,l,m) P ‐values by two‐tailed unpaired Student's t ‐test.

    Journal: Advanced Science

    Article Title: A Mammalian Conserved Circular RNA CircLARP1B Regulates Hepatocellular Carcinoma Metastasis and Lipid Metabolism

    doi: 10.1002/advs.202305902

    Figure Lengend Snippet: CircLARP1B destabilizes LKB1 mRNA via perturbing HNRNPD. a–d) Stability assay of LKB1 mRNA and the steady levels of LKB1 protein (examined by western blotting) in human PLC cells (a,b) and murine Hepa1‐6 cells (c,d) treated siRNA against HNRNPD. siNC, negative control siRNA with scrambled sequences. e) Overall experimental strategy of eIF4E and eIF4G1 RIP assays. RNase I is introduced to digest unprotected RNAs across the IP procedure. Western blots showing HNRNPD knockdown efficiency and efficient IPs of eIF4E and eIF4G1 in PLC cells treated with siRNA against HNRNPD (right). ACTB protein acted as the loading control. f) Primers against various regions of LKB1 mRNA (top) and enrichment of LKB1 mRNA regions with eIF4E or eIF4G1 by RT‐qPCR (bottom). g,h) Stability assay of LKB1 mRNA (g) and the steady levels of LKB1 protein (h) in WT or circLARP1B‐Def PLC cells. i,j) Stability assay of Lkb1 mRNA (i) and the steady levels of Lkb1 protein (j) in Hepa1‐6 cells treated with shcircLARP1B or shCtrl. shCtrl, shRNA control that generates siRNA of scrambled sequences; shcircLARP1B, shRNA against the murine circLARP1B BSJ. k) In vitro competing assay of purified HNRNPD protein for equal moles of in vitro synthesized circLARP1B and LKB1 3′ UTR. An illustration of the assay was shown (top). Semiquantitative RT‐PCR gels and RT‐qPCR for circLARP1B and LKB1 3′ UTR were indicated (bottom). LKB1 3′ UTR, in vitro transcribed LKB1 3′ UTR fragments with the HNRNPD binding sequence. l) Association of LKB1 mRNA examined by RT‐qPCR of HNRNPD RIP in PLC cells treated with oligodeoxynucleotide antisense to two HNRNPD binding motifs in circLARP1B (ODN‐AS) or the control (ODN‐Ctrl, ODN with scrambled sequences). Two motifs with reverse complementary sequences were indicated with underlines. PS, phosphorothioate; 2′‐OMe, 2′‐ O ‐methyl. Western blot images indicate successful IP of HNRNPD protein. Enrichment, normalized to IgG. m) Western blotting and the corresponding quantification showing the steady level of LKB1 protein in PLC cells transfected with ODN‐AS or ODN‐Ctrl. (b,d,h,j,m) The grayscale statistics of western blotting were performed by ImageJ. (a–d,f–m) Data are shown as mean ± SD from three independent experiments. (a,c,g,i) P ‐values by two‐way ANOVA test. (b,d,f,h,j,l,m) P ‐values by two‐tailed unpaired Student's t ‐test.

    Article Snippet: The shRNA against the BSJ of human or murine circLARP1B was cloned into the vector pLKO.1 (Sigma) and the negative‐control shRNA (shCtrl, MFCD07785395) was obtained from the MISSION shRNA Library (Sigma).

    Techniques: Stability Assay, Western Blot, Negative Control, Quantitative RT-PCR, shRNA, In Vitro, Purification, Synthesized, Reverse Transcription Polymerase Chain Reaction, Binding Assay, Sequencing, Protein Enrichment, Transfection, Two Tailed Test

    CircLARP1B deficiency in mice causes liver changes attributable to Lkb1 surplus. a) Strategy of knockout (KO) reverse‐complementary sequence in mouse Larp1b intron 4 using CRISPR‐Cas9. PCR products of mouse genotyping are shown. WT, wildtype; circLARP1B −/− , KO of the intronic reverse‐complementary sequences; B1, mouse B1 repeat. b) RT‐qPCR analysis of the steady levels and nascent levels (with nuclear run‐on assay) of circLARP1B and Larp1b mRNA in WT and circLARP1B −/− mouse liver. Data are from three independent experiments. c) Representative Oil Red O staining and the quantification in WT and circLARP1B −/− mouse liver ( N = 5 per group). Nuclei stained with hematoxylin (blue). Scale bar: 50 µm. d) Representative IHC staining and quantification of the proteins in liver from WT and circLARP1B −/− mice ( N = 5 per group). Scale bar: 50 µm. AOD, average optical density. e) Western blot of the indicated proteins in livers from WT or circLARP1B −/− mice. f) Representative Lkb1 IHC staining in livers from WT or circLARP1B −/− mice with the intravenous tail injection of AAV8‐shCtrl or AAV8‐shLkb1 for three weeks ( N = 5 per group). Scale bar: 50 µm. g) Representative Oil Red O staining in liver from WT or circLARP1B −/− mice with AAV8‐shCtrl or AAV8‐shLkb1 injection ( N = 5 per group). shCtrl, negative control shRNA construct that gives rise to siRNA with scrambled sequences. Nuclei stained with hematoxylin (blue). Scale bar: 50 µm. h) Representative IHC staining of the indicated proteins in liver from WT or circLARP1B −/− mice with AAV8‐shCtrl or AAV8‐shLkb1 injection ( N = 5 per group). Scale bar: 50 µm. i) Western blot of the indicated proteins in livers from WT or circLARP1B −/− mice with AAV8‐shCtrl or AAV8‐shLkb1 injection. Data are shown as mean ± SD. (c,g) Lipid level is defined as the percentage of Oil Red positive area calculated by Image‐Pro plus. (d,f,h) The IHC signal is defined as the average optical density (AOD) calculated by ImageJ. (e,i) The grayscale statistics of western blotting was performed by ImageJ. (c–i) All animals were kept in a controlled environment (23–25 °C with a 12‐h light‐dark cycle and lights on at 8:00 AM), on normal diet feeding with free access to water; all data were from mice at 9:00 AM. (b–d,f–h) P ‐values by two‐tailed unpaired Student's t ‐test.

    Journal: Advanced Science

    Article Title: A Mammalian Conserved Circular RNA CircLARP1B Regulates Hepatocellular Carcinoma Metastasis and Lipid Metabolism

    doi: 10.1002/advs.202305902

    Figure Lengend Snippet: CircLARP1B deficiency in mice causes liver changes attributable to Lkb1 surplus. a) Strategy of knockout (KO) reverse‐complementary sequence in mouse Larp1b intron 4 using CRISPR‐Cas9. PCR products of mouse genotyping are shown. WT, wildtype; circLARP1B −/− , KO of the intronic reverse‐complementary sequences; B1, mouse B1 repeat. b) RT‐qPCR analysis of the steady levels and nascent levels (with nuclear run‐on assay) of circLARP1B and Larp1b mRNA in WT and circLARP1B −/− mouse liver. Data are from three independent experiments. c) Representative Oil Red O staining and the quantification in WT and circLARP1B −/− mouse liver ( N = 5 per group). Nuclei stained with hematoxylin (blue). Scale bar: 50 µm. d) Representative IHC staining and quantification of the proteins in liver from WT and circLARP1B −/− mice ( N = 5 per group). Scale bar: 50 µm. AOD, average optical density. e) Western blot of the indicated proteins in livers from WT or circLARP1B −/− mice. f) Representative Lkb1 IHC staining in livers from WT or circLARP1B −/− mice with the intravenous tail injection of AAV8‐shCtrl or AAV8‐shLkb1 for three weeks ( N = 5 per group). Scale bar: 50 µm. g) Representative Oil Red O staining in liver from WT or circLARP1B −/− mice with AAV8‐shCtrl or AAV8‐shLkb1 injection ( N = 5 per group). shCtrl, negative control shRNA construct that gives rise to siRNA with scrambled sequences. Nuclei stained with hematoxylin (blue). Scale bar: 50 µm. h) Representative IHC staining of the indicated proteins in liver from WT or circLARP1B −/− mice with AAV8‐shCtrl or AAV8‐shLkb1 injection ( N = 5 per group). Scale bar: 50 µm. i) Western blot of the indicated proteins in livers from WT or circLARP1B −/− mice with AAV8‐shCtrl or AAV8‐shLkb1 injection. Data are shown as mean ± SD. (c,g) Lipid level is defined as the percentage of Oil Red positive area calculated by Image‐Pro plus. (d,f,h) The IHC signal is defined as the average optical density (AOD) calculated by ImageJ. (e,i) The grayscale statistics of western blotting was performed by ImageJ. (c–i) All animals were kept in a controlled environment (23–25 °C with a 12‐h light‐dark cycle and lights on at 8:00 AM), on normal diet feeding with free access to water; all data were from mice at 9:00 AM. (b–d,f–h) P ‐values by two‐tailed unpaired Student's t ‐test.

    Article Snippet: The shRNA against the BSJ of human or murine circLARP1B was cloned into the vector pLKO.1 (Sigma) and the negative‐control shRNA (shCtrl, MFCD07785395) was obtained from the MISSION shRNA Library (Sigma).

    Techniques: Knock-Out, Sequencing, CRISPR, Quantitative RT-PCR, Nuclear Run-on Assay, Staining, Immunohistochemistry, Western Blot, Injection, Negative Control, shRNA, Construct, Two Tailed Test

    Fig. 3 A20 inhibited antitumor immune response in vivo. a The expression of A20 in mice CT26-luc-GFP cells. b The cell proliferation of CT26- luc-GFP cells detected by CCK8 kit, n = 4. c The experimental scheme of the animal study. d The in vivo images of mice tumors with different treatments were detected by the IVIS bioluminescence imaging system, n = 7. e Statistical analysis of total flux from the IVIS bioluminescence images. f The representative images of the metastatic nodes in lung from BALB/C mice. g The survival curve of mice, n = 7. h The experimental scheme of the animal study. i The images of tumors excised from BALB/C mice at the end of experiments, n = 6. j Tumor weights of the four treatment groups, n = 6. k Tumor growth curves of the four treatment groups, n = 6. l The images of tumors excised from BALB/C mice at the end of experiments, n = 8. m Tumor weights of the four treatment groups, n = 8. n Tumor growth curves of the four treatment groups, n = 8. o–v The infiltration of CD3 (+) (X400), CD8 (+) (X400), CD4 (+) (X200), and Granzyme B(+) (X400) T cells detected by immunohistochemical staining. p-value was calculated by one-way ANOVA analysis. Shctrl+IgG, n = 7, Shctrl+αPD-1, n = 5, A20sh4+IgG, n = 7, A20sh4+αPD-1, n = 3. w–y Flow cytometry analysis of CD8 (+) and CD4 ( + ) T cells of mice spleens (n = 4 per group). Data was represented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant

    Journal: Signal transduction and targeted therapy

    Article Title: A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal.

    doi: 10.1038/s41392-023-01545-x

    Figure Lengend Snippet: Fig. 3 A20 inhibited antitumor immune response in vivo. a The expression of A20 in mice CT26-luc-GFP cells. b The cell proliferation of CT26- luc-GFP cells detected by CCK8 kit, n = 4. c The experimental scheme of the animal study. d The in vivo images of mice tumors with different treatments were detected by the IVIS bioluminescence imaging system, n = 7. e Statistical analysis of total flux from the IVIS bioluminescence images. f The representative images of the metastatic nodes in lung from BALB/C mice. g The survival curve of mice, n = 7. h The experimental scheme of the animal study. i The images of tumors excised from BALB/C mice at the end of experiments, n = 6. j Tumor weights of the four treatment groups, n = 6. k Tumor growth curves of the four treatment groups, n = 6. l The images of tumors excised from BALB/C mice at the end of experiments, n = 8. m Tumor weights of the four treatment groups, n = 8. n Tumor growth curves of the four treatment groups, n = 8. o–v The infiltration of CD3 (+) (X400), CD8 (+) (X400), CD4 (+) (X200), and Granzyme B(+) (X400) T cells detected by immunohistochemical staining. p-value was calculated by one-way ANOVA analysis. Shctrl+IgG, n = 7, Shctrl+αPD-1, n = 5, A20sh4+IgG, n = 7, A20sh4+αPD-1, n = 3. w–y Flow cytometry analysis of CD8 (+) and CD4 ( + ) T cells of mice spleens (n = 4 per group). Data was represented as the mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; n.s. not significant

    Article Snippet: The shRNAs of A20 or STC1 and a negative shRNA control (shctrl) were cloned into pSIH-H1-puro lentivector (Addgene, USA).

    Techniques: In Vivo, Expressing, Imaging, Immunohistochemical staining, Staining, Flow Cytometry